![Kathryn Haviland](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Kathryn Haviland
Vorsitzender bei
FULCRUM THERAPEUTICS, INC.
Vermögen: 161 755 $ am 31.05.2026
Profil
Kathryn Haviland ist Mitglied des Vorstands von Fulcrum Therapeutics, Inc. und Chief Operating Officer bei Blueprint Medicines Corp. sowie Mitglied der Harvard Business School Health Industry Alumni Association und Mitglied des Biopharma Executive Council. Frau Haviland hatte zuvor die Position des Vice President-Rare Diseases bei Idera Pharmaceuticals, Inc. inne, Head-Commercial Development bei Sarepta Therapeutics, Inc. und Executive Director-Commercial Development bei PTC Therapeutics, Inc. Sie erhielt einen Undergraduate-Abschluss von der Wesleyan University und einen MBA von der Harvard Business School.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 09.06.2026 | 7’437 ( 0.01% ) | 161 755 $ | 31.05.2026 | |
| 30.06.2026 | 0 ( -.--% ) | - $ | 31.05.2026 | |
AVALYN PHARMA INC -.--% | 30.04.2026 | 0 ( -.--% ) | - $ | 31.05.2026 |
Aktive Positionen von Kathryn Haviland
| Unternehmen | Position | Beginn |
|---|---|---|
| FULCRUM THERAPEUTICS, INC. | Vorsitzender | 10.01.2022 |
| BICARA THERAPEUTICS INC. | Direktor/Vorstandsmitglied | 21.09.2023 |
| AVALYN PHARMA INC. | Direktor/Vorstandsmitglied | 01.03.2026 |
Harvard Business School Health Industry Alumni Association | Corporate Officer/Principal | - |
Biopharma Executive Council
 Biopharma Executive Council Miscellaneous Commercial ServicesCommercial Services Operates as biotech and pharmaceutical executive level membership council | Corporate Officer/Principal | - |
Ehemalige bekannte Positionen von Kathryn Haviland
| Unternehmen | Position | Ende |
|---|---|---|
| BLUEPRINT MEDICINES CORPORATION | Vorstandsvorsitzender | 01.01.2026 |
Idera Pharmaceuticals, Inc.
 Idera Pharmaceuticals, Inc. BiotechnologyHealth Technology Develops drug candidates for oncology and rare disease indications | Corporate Officer/Principal | 01.12.2015 |
| SAREPTA THERAPEUTICS, INC. | Corporate Officer/Principal | 01.04.2014 |
| PTC THERAPEUTICS, INC. | Corporate Officer/Principal | 01.06.2012 |
Ausbildung von Kathryn Haviland
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
73
Beziehungen ersten Grades
11
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 11 |
|---|---|
Idera Pharmaceuticals, Inc.
Idera Pharmaceuticals, Inc. BiotechnologyHealth Technology Develops drug candidates for oncology and rare disease indications | Health Technology |
Sarepta Therapeutics, Inc.
 Sarepta Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Manufactures micro-dystrophin gene therapy | Health Technology |
PTC Therapeutics, Inc.
 PTC Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops, manufactures and markets clinically differentiated medicines for neurodegenerative diseases | Health Technology |
Avalyn Pharma Inc.
 Avalyn Pharma Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company that develops inhaled therapies to treat rare respiratory & interstitial lung diseases | Health Technology |
Wesleyan University
 Wesleyan University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Blueprint Medicines Corp.
 Blueprint Medicines Corp. BiotechnologyHealth Technology Develops cancer therapies that harness the growing understanding of the molecular blueprint of cancer | Health Technology |
Harvard Business School Health Industry Alumni Association | |
Harvard Business School
 Harvard Business School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Fulcrum Therapeutics, Inc.
 Fulcrum Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops medicines for patients by transforming gene regulation in disease | Health Technology |
Biopharma Executive Council
Biopharma Executive Council Miscellaneous Commercial ServicesCommercial Services Operates as biotech and pharmaceutical executive level membership council | Commercial Services |
Bicara Therapeutics, Inc.
 Bicara Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company that develops and sells therapeutics for tumors | Health Technology |
Wählen Sie MarketScreener 
